Chief of Staff

Molecule’s story starts with patients and researchers. We imagine a world where patients directly fund researchers developing the next therapeutic breakthrough they need. A world where accessible, innovative therapeutics are created through collaborative drug development and fuelled by early R&D funding - operating at the intersection of biotechnology and decentralization, we are building the frameworks and platform to do exactly this.

Over the past 12 months, we have grown our team from 3 to 20 and recently closed a $12.7m Seed round.